1:2:1 Podcast : Stem Cells
Irving Weissman on Stanford's new stem cell building
The Lorry I. Lokey Stem Cell Research Building is the largest such facility in the country.
Irving Weissman on fraudulent stem cell treatments
Irving Weissman, MD, director of Stanford's Institute for Regenerative Medicine and Stem Cell Biology, believes that hundreds of millions of dollars are being spent on unproven and potentially dangerous clinical treatments.
Marius Wernig on the future of stem cell therapy
Scientists at the School Medicine have succeeded in transforming mouse skin cells in a laboratory dish directly into functional nerve cells with the application of just three genes.
Francis Collins on the National Institutes of Health
In this wide-ranging discussion, Francis Collins, MD, PhD, director of the National Institutes of Health, shares his thoughts on the agency's stimulus funding, the not-so-easy task of securing additional funds for the agency's FY 2011 budget, and groundbreaking stem cell and cancer research being funded through the Recovery Act.
Christopher Scott on human embryonic stem cell lines
For the past eight years, scientists who wanted to use federal funds for research on human embryonic stem cells had to restrict their studies to 21 cell lines approved by the National Institutes of Health.
Irving Weissman on proposed NIH stem cell guidelines
Irving Weissman, MD, the director of stem cell research at the School of Medicine says he is troubled by draft guidelines recently issued by the National Institutes of Health that would prohibit federal funding for research on stem cell lines created through a technique sometimes referred to as "therapeutic cloning" or somatic cell nuclear transfer.
Longaker on stem cell research
Michael Longaker, MD, discusses the state and future of stem cell research. Longaker is the deputy director of Stanford's Stem Cell Biology and Regenerative Medicine Institute and the director of the Program in Regenerative Medicine.